Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted

Journal of Virology

Volumn 70, Issue 10, 1996, Pages 7030-7038

  Zhou, Heshan ^a,b   O'Neal, Wanda ^a   Morral, Núria ^a,b   Beaudet, Arthur L ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BETA GALACTOSIDASE;

ADENOVIRUS; ARTICLE; CELL LINE; CONTROLLED STUDY; ENZYME RECONSTITUTION; ESCHERICHIA COLI; EXPRESSION VECTOR; GENE TARGETING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0029843063     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.10.7030-7038.1996     Document Type: Article

References (54)

1. Amalfitano, A., C. R. Begy, and J. S. Chamberlain. 1996. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc. Natl. Acad. Sci. USA 93:3352-3356.
2. Armentano, D., C. C. Sookdeo, K. M. Hehir, R. J. Gregory, J. A. St. George, G. A. Prince, S. C. Wadsworth, and A. E. Smith. 1995. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum. Gene Ther. 6:1343-1353.
3. Barr, D., J. Tubb, D. Ferguson, A. Scaria, A. Lieber, C. Wilson, J. Perkins, and M. A. Kay. 1995. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2:151-155.
4. Berkner, K. L. 1988. Development of adenovirus vectors for the expression of heterologous genes. BioTechniques 6:616-629.
5. Bett, A. J., W. Haddara, L. Prevec, and F. L. Graham. 1994. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. USA 91:8802-8806.
6. Boucher, R. C. 1996. Current status of CF gene therapy. Trends Genet. 12:81-84.
7. Bramson, J. L., F. L. Graham, and J. Gauldie. 1995. The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr. Opin. Biotechnol. 6:590-595.
8. Brody, S. L., M. Metzger, C. Danel, M. A. Rosenfeld, and R. G. Crystal. 1994. Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum. Gene Ther. 5:821-836.
9. Brough, D. E., V. Cleghon, and D. F. Klessig. 1992. Construction, characterization, and utilization of cell lines which inducibly express the adenovirus DNA-binding protein. Virology 190:624-634.
10. Chang, L., and T. Shenk. 1990. The adenovirus DNA-binding protein stimulates the rate of transcription directed by adenovirus and adeno-associated virus promoters. J. Virol. 64:2103-2109.
11. Couch, R. B., R. M. Chanock, T. R. Cate, D. J. Lang, V. Knight, and R. J. Huebner. 1963. Immunization with types 4 and 7 adenovirus by selective infection of the intestinal tract. Am. Rev. Respir. Dis. 88:394-403.
12. Crystal, R. G. 1995. Transfer of genes to humans: early lessons and obstacles to success. Science 270:404-410.
13. Crystal, R. G., N. G. McElvaney, M. A. Rosenfeld, C. Chu, A. Mastrangeli, J. G. Hay, S. L. Brody, H. A. Jaffe, N. T. Eissa, and C. Danel. 1994. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8:42-51.
14. Engelhardt, J. F., X. Ye, B. Doranz, and J. M. Wilson. 1994. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91:6196-6200.
15. Ensinger, M. J., and H. S. Ginsberg. 1972. Selection and preliminary characterization of temperature-sensitive mutants of type 5 adenovirus. J. Virol. 10:328-339.
16. - recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and dogs. Gene Ther. 3:217-222.
17. Fisher, K. J., H. Choi, J. Burda, S. Chen, and J. M. Wilson. 1996. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217:11-22.
18. French, B. A., W. Mazur, N. M. Ali, R. S. Geske, J. P. Finnigan, G. P. Rodgers, R. Roberts, and A. E. Raizner. 1994. Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation 90:2402-2413.
19. Ginsberg, H. S., J. F. Williams, W. H. Doerfler, and H. Shimojo. 1973. Proposed nomenclature for mutants of adenoviruses. J. Virol. 12:663-664.
20. Goldman, M. J., L. A. Litzky, J. F. Engelhardt, and J. M. Wilson. 1995. Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study. Hum. Gene Ther. 6:839-851.
21. Gorziglia, M. I., M. J. Kadan, S. Yei, J. Lim, G. M. Lee, R. Luthra, and B. C. Trapnell. 1996. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70: 4173-4178.
22. Graham, F. L. 1984. Covalently closed circles of human adenovirus DNA are infectious. EMBO J. 3:2917-2922.
23. Graham, F. L., and L. Prevec. 1991. Manipulation of adenovirus vectors, p. 109E. In J. Murray (ed.), Methods in molecular biology. The Human Press, Inc., Clifton, NJ.
24. Graham, F. L., J. Rudy, and P. Brinkley. 1989. Infectious circular DNA of human aderovirus type 5: regeneration of viral DNA termini from molecules lacking terminal sequences. EMBO J. 8:2077-2085.
25. Graham, F. L., and J. Smiley. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-72
26. Herrmann, F. 1995. Cancer gene therapy: principles, problems, and perspectives. J. Mol. Med. 73:157-163.
27. Kay, M. A., F. Graham, F. Leland, and S. L. Woo. 1995. Therapeutic serum concentrations of human α1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology 21:815-819.
28. Klessig, D. F., D. E. Brough, and V. Cleghon. 1984. Introduction, stable integration, and controlled expression of a chimeric adenovirus gene whose product is toxic to the recipient human cell. Mol. Cell. Biol. 4:1354-1362.
29. Kochanek, S., P. R. Clemens, K. Mitani, H.-H. Chen, S. Chan, and C. T. Caskey. 1996. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc. Natl. Acad. Sci. USA 93:5731-5736.
30. Krougliak, V., and F. L. Graham. 1995. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum. Gene Ther. 6:1575-1586.
31. McGrory, W. J., D. S. Bautista, and F. L. Graham. 1988. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology 163:614-617.
32. Mittereder, N., S. Yei, C. Bachurski, J. Cuppoletti, J. A. Whitsett. P. Tolstoshev, and B. C. Trapnell. 1994. Evaluation of the efficacy and safety of in vitro, adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA. Hum. Gene Ther. 5:717-729.
33. Mizushima, S., and S. Nagata. 1990. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res. 18:5322.
34. Morgan, J. E. 1994. Cell and gene therapy in Duchenne muscular dystrophy. Hum. Gene Ther. 5:165-173.
35. Morsy, M. A., E. L. Alford, A. Bett, F. L. Graham, and C. T. Caskey. 1993. Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes. J. Clin. Invest. 92:1580-1586.
36. Neve, R. L. 1993. Adenovirus vectors enter the brain. Trends Neurosci. 16:251-253.
37. Nicolas, J. C., P. Sarnow, M. Girard, and A. J. Levine. 1983. Host range temperature-conditional mutants in the adenovirus DNA binding protein are defective in the assembly of infectious virus. Virology 126:228-239.
38. O'Connor, R. J., and P. Hearing. 1994. Mutually exclusive interaction of adenovirus E4-6/7 protein and the retinoblastoma gene product with internal domains of E2F-1 and DP-1. J. Virol. 68:6848-6862.
39. O'Neal, W. K., and A. L. Beaudet. 1994. Somatic gene therapy for cystic fibrosis. Hum. Mol. Genet. 3:1497-1502.
40. Rice, S. A., and D. F. Klessig. 1985. Isolation and analysis of adenovirus type 5 mutants containing deletions in the gene encoding the DNA-binding protein. J. Virol. 56:767-778.
41. Soriano, P., C. Montgomery, R. Geske, and A. Bradley. 1991. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702.
42. Stillman, B. W. 1985. Biochemical and genetic analysis of adenovirus DNA replication in vitro, p. 1-27. In J. K. Setlow and A. Hollaender (ed.). Genetic engineering principles and methods. Plenum Press, New York.
43. Stratford-Perricaudet, L. D., I. Makeh, M. Perricaudet, and P. Briand. 1992. Widespread long term gene transfer to mouse skeletal muscles and heart. J. Clin. Invest. 90:625-630.
44. Stratford-Perricaudet, L., and M. Perricaudet. 1991. Gene transfer into animals: the promise of adenovirus. Hum. Gene Ther. 219:51-61.
45. Top, F. H., Jr., E. L. Buescher, W. H. Bancroft, and P. K. Russell. 1971. Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J. Infect. Dis. 124:155-160.
46. Tsuji, M., P. C. van der Vliet, and G. R. Kitchingman. 1991. Temperature-sensitive mutants of adenovirus single-stranded DNA-binding protein. J. Biol. Chem. 266:16178-16187.
47. van der Vliet, P. C., A. J. Levine, M. S. Ensinger, and H. S. Ginsberg. 1975. Thermolabile DNA binding proteins from cells infected with a temperature-sensitive mutant of adenovirus defective in viral DNA synthesis. J. Virol. 15:348-354.
48. van Ormondt, H., and F. Galibert. 1984. Nucleotide sequences of adenovirus DNAs, p. 73-142. In W. Doerfler (ed.), The molecular biology of adenoviruses 2. Springer-Verlag, Berlin.
49. Voelkerding, K., and D. F. Klessig. 1986. Identification of two nuclear subclasses of the adenovirus type 5-encoded DNA-binding protein. J. Virol. 60:353-362.
50. Wang, Q., X. Jia, and M. H. Finer. 1995. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther. 2:775-783.
51. Yang, Y., F. A. Nunes, K. Berencsi, E. E. Furth, E. Gönczöl, and J. M. Wilson. 1994. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91:4407-4411.
52. Yang, Y., F. A. Nunes, K. Berencsi, E. Gönczöl, J. F. Engelhardt, and J. M. Wilson. 1994. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat. Genet. 7:362-369.
53. Yei, S., N. Mittereder, S. Wert, J. A. Whitsett, R. W. Wilmott, and B. C. Trapnell. 1994. In viro evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum. Gene Ther. 5:731-744.
54. Zsengeller, Z. K., S. E. Wert, W. M. Hull, X. Hu, S. Yei, B. C. Trapnell, and J. A. Whitsett. 1995. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum. Gene Ther. 6:457-467.